Edition:
United States

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

2.04USD
17 Jan 2017
Change (% chg)

$-0.07 (-3.32%)
Prev Close
$2.11
Open
$2.10
Day's High
$2.10
Day's Low
$2.03
Volume
303,894
Avg. Vol
305,357
52-wk High
$3.42
52-wk Low
$1.81

GERN.OQ

Chart for GERN.OQ

About

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for... (more)

Overall

Beta: 2.81
Market Cap(Mil.): $335.80
Shares Outstanding(Mil.): 159.15
Dividend: --
Yield (%): --

Financials

  GERN.OQ Industry Sector
P/E (TTM): -- 45.90 30.76
EPS (TTM): -0.19 -- --
ROI: -21.33 -1.00 14.82
ROE: -21.33 -0.71 16.24

BRIEF-Geron Corp reports loss per share of $0.02

* Geron Corporation reports third quarter 2016 financial results and recent events

Nov 03 2016

BRIEF-Geron Corp and Janssen Pharmaceuticals enter into a license agreement

* On September 15, 2016, co, Janssen Pharmaceuticals Inc entered into a license agreement - SEC filing

Sep 19 2016

BRIEF-Geron Corp Q2 loss per share $0.05

* Geron corporation reports second quarter 2016 financial results and recent events

Aug 03 2016

Competitors

Earnings vs. Estimates